Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes.
paper
Cited
Public
Unavailable
- Authors
- Nakajima, M; Yamamoto, T; Nunoya, K; Yokoi, T; Nagashima, K; Inoue, K; Funae, Y; Shimada, N; Kamataki, T; Kuroiwa, Y
- Year
- 1996
- Journal
- The Journal of pharmacology and experimental therapeutics
- PMID
- 8627511
Nicotine is primarily metabolized to cotinine, and cotinine is further metabolized to trans-3'-hydroxycotinine in human liver, which is a major metabolite of nicotine in humans. We studied the formation of trans-3'-hydroxycotinine from cotinine in human liver microsomes. trans-3'-Hydroxycotinine formation demonstrated single enzyme Michaelis-Menten kinetics (Km, 234.5 +/- 26.8 MicroM; Vmax, 37.2 +/- 2.4 pmol/min/mg protein). Significant correlation (r = .967, P < .001) between cotinine 3'-hydroxylase activities at low (50 microM) and high (1 microM) cotinine concentrations in 20 human liver microsomes suggested the contribution of a single enzyme to cotinine 3'-hydroxylation. The cotinine 3'-hydroxylase activity correlated significantly with immunoreactive cytochrome P450 (CYP)2A6 contents (r = .756, P < .01) and coumarin 7-hydroxylase activity (r = .887, P < .001). The cotinine 3'-hydroxylase activity was inhibited by coumarin, alpha-naphthoflavone, chlorzoxazone and anti-rat CYP2A1 antibodies. Microsomes of B-lymphoblastoid cells expressing human CYP2A6 exhibited cotinine 3'-hydroxylase activity. The Km value of the expressed CYP2A6 (264.7 microM) was almost identical to that of human liver microsomes. In conclusion, cotinine 3'-hydroxylation appears to be catalyzed solely by CYP2A6 in humans. Cotinine is a candidate for a new substrate for CYP2A6 in humans.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Wearable sweat nicotine biosensor based on a nicotine oxidoreductase and its natural electron acceptor | Zhang Z et al. | β | 2025 | β |
| CYP2A6 associates with respiratory disease risk and younger age of diagnosis: a phenome-wide association Mendelian Randomization study. | Giratallah H et al. | β | 2024 | β |
| The hidden impact: the rate of nicotine metabolism and kidney health. | Wang X et al. | β | 2024 | β |
| Biomarkers of exposure in urine of active smokers, non-smokers, and vapers. | Gallart-Mateu D et al. | β | 2023 | β |
| CYP2C19 Plays a Major Role in the Hepatic <i>N</i>-Oxidation of Cotinine. | Perez-Paramo YX et al. | β | 2023 | β |
| Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers. | Perez-Paramo YX et al. | β | 2023 | β |
| Influence of CYP2A6 Genetic Variation, Nicotine Dependence Severity, and Treatment on Smoking Cessation Success. | Chenoweth MJ et al. | β | 2023 | β |
| Inhibition of Nicotine Metabolism by Cannabidiol (CBD) and 7-Hydroxycannabidiol (7-OH-CBD). | Nasrin S et al. | β | 2023 | β |
| Association of the Time to First Cigarette and the Prevalence of Chronic Respiratory Diseases in Chinese Elderly Population. | Wang C et al. | β | 2022 | β |
| Review of HPLC-MS methods for the analysis of nicotine and its active metabolite cotinine in various biological matrices. | Jin S et al. | β | 2022 | β |
| Serum Concentrations of Cotinine and Trans-3'-Hydroxycotinine in US Adults: Results From Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study. | Sosnoff CS et al. | β | 2022 | β |
| Analyses of nicotine metabolism biomarker genetics stratified by sex in African and European Americans. | Chenoweth MJ et al. | β | 2021 | β |
| An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity. | Kahma H et al. | β | 2021 | β |
| Biochemistry of nicotine metabolism and its relevance to lung cancer. | Murphy SE | β | 2021 | β |
| Genome-wide association meta-analysis of nicotine metabolism and cigarette consumption measures in smokers of European descent. | Buchwald J et al. | β | 2021 | β |
| Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies. | Giratallah HK et al. | β | 2021 | β |
| Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism. | Perez-Paramo YX et al. | β | 2021 | β |
| Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations. | El-Boraie A et al. | β | 2021 | β |
| Analysis of Nicotine Metabolites in Hair and Nails Using QuEChERS Method Followed by Liquid Chromatography-Tandem Mass Spectrometry. | Kim J et al. | β | 2020 | β |
| Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity. | El-Boraie A et al. | β | 2020 | β |
| Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations. | Claw KG et al. | β | 2020 | β |
| Evaluating metronidazole as a novel, safe CYP2A6 phenotyping probe in healthy adults. | Stancil SL et al. | β | 2019 | β |
| A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine. | Taghavi T et al. | β | 2018 | β |
| Cigarette consumption and biomarkers of nicotine exposure during pregnancy and postpartum. | Taghavi T et al. | β | 2018 | β |
| Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. | Chenoweth MJ et al. | β | 2018 | β |
| Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways. | Taghavi T et al. | β | 2018 | β |
| Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism. | Tanner JA et al. | β | 2018 | β |
| P450 Pharmacogenetics in Indigenous North American Populations. | Henderson LM et al. | β | 2018 | β |
| Preparing the Way: Exploiting Genomic Medicine to Stop Smoking. | Bierut LJ et al. | β | 2018 | β |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | β | 2018 | β |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | β | 2018 | β |
| Pharmacogenetic Optimization of Smoking Cessation Treatment. | Chenoweth MJ et al. | β | 2017 | β |
| Variation in CYP2A6 Activity and Personalized Medicine. | Tanner JA et al. | β | 2017 | β |
| Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. | Tanner JA et al. | β | 2017 | β |
| Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily. | Cunningham CS et al. | β | 2016 | β |
| Genome-Wide Association of the Laboratory-Based Nicotine Metabolite Ratio in Three Ancestries. | Baurley JW et al. | β | 2016 | β |
| Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. | Upreti VV et al. | β | 2016 | β |
| Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. | Fagan P et al. | β | 2016 | β |
| Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio. | Allenby CE et al. | β | 2016 | β |
| Smokescreen: a targeted genotyping array for addiction research. | Baurley JW et al. | β | 2016 | β |
| The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio. | Chenoweth MJ et al. | β | 2016 | β |
| Associations Between Genetic Ancestries and Nicotine Metabolism Biomarkers in the Multiethnic Cohort Study. | Wang H et al. | β | 2015 | β |
| Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. | Fagan P et al. | β | 2015 | β |
| Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer. | Beyerle J et al. | β | 2015 | β |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | β | 2015 | β |
| Menthol cigarette smoking and obesity in young adult daily smokers in Hawaii. | Antonio AM et al. | β | 2015 | β |
| N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. | LeMasters GK et al. | β | 2015 | β |
| New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine. | Grizzell JA et al. | β | 2015 | β |
| Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. | Tanner JA et al. | β | 2015 | β |
| Pharmacogenetics of nicotine and associated smoking behaviors. | Tanner JA et al. | β | 2015 | β |
| Smoking topography in Korean American and white men: preliminary findings. | Chung S et al. | β | 2015 | β |
| Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. | Hamilton DA et al. | β | 2015 | β |
| The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. | Patel YM et al. | β | 2015 | β |
| Toxicity of aerosols of nicotine and pyruvic acid (separate and combined) in Sprague-Dawley rats in a 28-day OECD 412 inhalation study and assessment of systems toxicology. | Phillips B et al. | β | 2015 | β |
| Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. | Chenoweth MJ et al. | β | 2014 | β |
| Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. | Piliguian M et al. | β | 2014 | β |
| Relationship between cotinine and trans-3'-hydroxycotinine glucuronidation and the nicotine metabolite ratio in Caucasian smokers. | Jacobson GA et al. | β | 2014 | β |
| Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. | Zhu AZ et al. | β | 2013 | β |
| Detection of tobacco-related biomarkers in urine samples by surface-enhanced Raman spectroscopy coupled with thin-layer chromatography. | Huang R et al. | β | 2013 | β |
| Feasibility of identifying the tobacco-related global metabolome in blood by UPLC-QTOF-MS. | Hsu PC et al. | β | 2013 | β |
| Metabolism of 7-ethoxycoumarin, safrole, flavanone and hydroxyflavanone by cytochrome P450 2A6 variants. | Uno T et al. | β | 2013 | β |
| Nicotine kinetics in zebra finches in vivo and in vitro. | Miksys S et al. | β | 2013 | β |
| Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. | Faseru B et al. | β | 2013 | β |
| Simultaneous determination of nicotine and cotinine in serum using high-performance liquid chromatography with fluorometric detection and postcolumn UV-photoirradiation system. | Yasuda M et al. | β | 2013 | β |
| Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes. | St Helen G et al. | β | 2013 | β |
| The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. | Zhu AZ et al. | β | 2013 | β |
| The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans. | Bloom AJ et al. | β | 2013 | β |
| The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. | Pearce RE et al. | β | 2013 | β |
| Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. | Zhu AZ et al. | β | 2013 | β |
| A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. | Cho MH et al. | β | 2012 | β |
| CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Ξ5'(1')iminium ion. | von Weymarn LB et al. | β | 2012 | β |
| CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. | Binnington MJ et al. | β | 2012 | β |
| Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. | Ferguson CS et al. | β | 2012 | β |
| Emerging genetics of COPD. | Berndt A et al. | β | 2012 | β |
| Pharmacologic characterization of a nicotine-discriminative stimulus in rhesus monkeys. | Cunningham CS et al. | β | 2012 | β |
| PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. | McDonagh EM et al. | β | 2012 | β |
| Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. | Hurley LL et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| Toxicity of nicotine by repeated intratracheal instillation to f344 rats. | Yokohira M et al. | β | 2012 | β |
| Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. | Khojasteh SC et al. | β | 2011 | β |
| Cytochrome P450 polymorphisms and drug-induced interstitial lung disease. | Schwaiblmair M et al. | β | 2011 | β |
| Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. | Jacob P et al. | β | 2011 | β |
| Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. | Yokota S et al. | β | 2011 | β |
| Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. | Rangiah K et al. | β | 2011 | β |
| Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. | Hien TT et al. | β | 2011 | β |
| The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. | Bloom J et al. | β | 2011 | β |
| Treatment for tobacco dependence: a potential application for stratified medicine? | Brock AJ et al. | β | 2011 | β |
| Association between nicotine metabolism and CYP2A6*1 and CYP2A6*4 genotypes in an Iranian population. | Heravi RE et al. | β | 2010 | β |
| Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. | Hukkanen J et al. | β | 2010 | β |
| Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. | Al Koudsi N et al. | β | 2010 | β |
| Internet suicide guidelines: report of a life-threatening poisoning using tobacco extract. | Schneider S et al. | β | 2010 | β |
| New CYP2A6 gene deletion and conversion variants in a population of Black African descent. | Mwenifumbo JC et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| The effect of menthol containing cigarettes on adult smokers' exposure to nicotine and carbon monoxide. | Wang J et al. | β | 2010 | β |
| A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. | Al Koudsi N et al. | β | 2009 | β |
| Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| Conceptual DFT properties-based 3D QSAR: analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. | Van Damme S et al. | β | 2009 | β |
| Genetic influences on individual differences in nicotine glucuronidation. | Lessov-Schlaggar CN et al. | β | 2009 | β |
| Polymorphism of human cytochrome P450 enzymes and its clinical impact. | Zhou SF et al. | β | 2009 | β |
| Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. | Tarning J et al. | β | 2009 | β |
| Utility and relationships of biomarkers of smoking in African-American light smokers. | Ho MK et al. | β | 2009 | β |
| A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. | Ho MK et al. | β | 2008 | β |
| Assessing dimensions of nicotine dependence: an evaluation of the Nicotine Dependence Syndrome Scale (NDSS) and the Wisconsin Inventory of Smoking Dependence Motives (WISDM). | Piper ME et al. | β | 2008 | β |
| CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives. | Sinues B et al. | β | 2008 | β |
| CYP2A6 polymorphisms and risk for tobacco-related cancers. | Rossini A et al. | β | 2008 | β |
| Inhibition and induction of human cytochrome P450 enzymes: current status. | Pelkonen O et al. | β | 2008 | β |
| Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. | Sharma G et al. | β | 2008 | β |
| Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. | Mwenifumbo JC et al. | β | 2008 | β |
| Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. | Patterson F et al. | β | 2008 | β |
| Application of nicotine enantiomers, derivatives and analogues in therapy of neurodegenerative disorders. | Pogocki D et al. | β | 2007 | β |
| Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. | Mwenifumbo JC et al. | β | 2007 | β |
| Human CYP2A6 is induced by estrogen via estrogen receptor. | Higashi E et al. | β | 2007 | β |
| Non-nicotinic therapies for smoking cessation. | Siu EC et al. | β | 2007 | β |
| Overview of the pharmacogenomics of cigarette smoking. | Ho MK et al. | β | 2007 | β |
| Pharmacogenetics and smoking cessation with nicotine replacement therapy. | Ray R et al. | β | 2007 | β |
| Population pharmacokinetics of nicotine and its metabolites I. Model development. | Levi M et al. | β | 2007 | β |
| Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. | Malaiyandi V et al. | β | 2006 | β |
| Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. | Guillem K et al. | β | 2006 | β |
| Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. | Siu EC et al. | β | 2006 | β |
| Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. | Lockman PR et al. | β | 2005 | β |
| CYP2A6 genetic polymorphisms and correlation with smoking status in Brazilians. | Vasconcelos GM et al. | β | 2005 | β |
| Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. | Malaiyandi V et al. | β | 2005 | β |
| Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. | Nakajima M et al. | β | 2005 | β |
| Metabolism and disposition kinetics of nicotine. | Hukkanen J et al. | β | 2005 | β |
| Metabolism of nicotine and cotinine by human cytochrome P450 2A13. | Bao Z et al. | β | 2005 | β |
| Three haplotypes associated with CYP2A6 phenotypes in Caucasians. | Haberl M et al. | β | 2005 | β |
| Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes. | Yamanaka H et al. | β | 2005 | β |
| A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. | Pitarque M et al. | β | 2004 | β |
| Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). | Dorne JL et al. | β | 2004 | β |
| Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. | Yamanaka H et al. | β | 2004 | β |
| Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. | Denton TT et al. | β | 2004 | β |
| Novel human CYP2A6 alleles confound gene deletion analysis. | Nakajima M et al. | β | 2004 | β |
| Postnatal expression of cytochrome P450 1A1, 2A3, and 2B1 mRNA in neonatal rat lung: influence of maternal nicotine exposure. | Gamieldien K et al. | β | 2004 | β |
| Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism. | Lewis DF et al. | β | 2004 | β |
| Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. | Saito S et al. | β | 2003 | β |
| Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). | Kiyotani K et al. | β | 2003 | β |
| Determination of the human cytochrome P450s involved in the metabolism of 2n-propylquinoline. | Belliard AM et al. | β | 2003 | β |
| Genetic influences on smoking behavior and nicotine dependence: a review. | Yoshimasu K et al. | β | 2003 | β |
| Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. | Tricker AR | β | 2003 | β |
| Accelerated metabolism of nicotine and cotinine in pregnant smokers. | Dempsey D et al. | β | 2002 | β |
| A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. | Daigo S et al. | β | 2002 | β |
| Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. | Nakajima M et al. | β | 2002 | β |
| Clinical phenotyping strategies in selection of tobacco smokers for future genotyping studies. | Domino EF et al. | β | 2002 | β |
| CYP2A6 genetic variation and potential consequences. | Xu C et al. | β | 2002 | β |
| Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. | Zeman MV et al. | β | 2002 | β |
| Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. | Yoshida R et al. | β | 2002 | β |
| Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. | Tyndale RF et al. | β | 2002 | β |
| Genotyping human CYP2A6 variants. | Goodz SD et al. | β | 2002 | β |
| Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. | Nakajima M et al. | β | 2002 | β |
| Novel mutations of the CYP2A6 gene in a Thai population with lowered capacity of coumarin 7-hydroxylation. | Kiyotani K et al. | β | 2002 | β |
| Summary of information on human CYP enzymes: human P450 metabolism data. | Rendic S | β | 2002 | β |
| CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. | Kitagawa K et al. | β | 2001 | β |
| Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. | Loriot MA et al. | β | 2001 | β |
| Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. | Pitarque M et al. | β | 2001 | β |
| Polymorphisms of CYP2A6 and its practical consequences. | Raunio H et al. | β | 2001 | β |
| Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. | Benowitz NL et al. | β | 2001 | β |
| CYP2A6: a human coumarin 7-hydroxylase. | Pelkonen O et al. | β | 2000 | β |
| Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. | Rao Y et al. | β | 2000 | β |
| Functional variants at CYP2A6: new genotyping methods, population genetics, and relevance to studies of tobacco dependence. | Zabetian CP et al. | β | 2000 | β |
| Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. | Oscarson M et al. | β | 1999 | β |
| Expression of CYP2A genes in human liver and extrahepatic tissues. | Koskela S et al. | β | 1999 | β |
| Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. | Oscarson M et al. | β | 1999 | β |
| Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. | Lewis DF et al. | β | 1999 | β |
| The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. | Kitagawa K et al. | β | 1999 | β |
| Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. | Yokoi T et al. | β | 1998 | β |
| Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. | Oscarson M et al. | β | 1998 | β |
| Human CYP2D6 and metabolism of m-chlorophenylpiperazine. | Rotzinger S et al. | β | 1998 | β |
| Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. | Li Y et al. | β | 1997 | β |
| Cotinine effects on nicotine metabolism. | Zevin S et al. | β | 1997 | β |
| The structure, function, and regulation of cytochrome P450 2A enzymes. | Honkakoski P et al. | β | 1997 | β |
| Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. | Bertz RJ et al. | β | 1997 | β |